BME100 f2015:Group4 1030amL2
|BME 100 Fall 2015|| Home |
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help
LAB 2: Means, Standard Deviations, t-test, and ANOVAs
An ANOVA was completed for the human data since multiple levels of dosages were present. A post-hoc was used due to a significant result on the ANOVA.
A t-test was completed for the rat data because only two levels of LPS were presented in this sample.
We are more than 99% confident that there is a significant difference in the Inflammotin protein levels, in pg/mL, between the four groups of humans receiving 0 mg, 5 mg, 10, mg, and 15 mg of LPS. We are more than 99% confident that there is a significant difference in the Inflammotin protein levels, in pg/mL, between 0 v. 5 mg, 5 v. 10 mg, 10 v. 15 mg, 0 v. 10 mg, 0 v. 15 mg, and 5 v. 15 mg of LPS. Therefore, there is sufficient evidence to conclude that there is a significant difference in the Inflammotin protein level in result of the difference in LPS dosage amounts.
Given the differing results between the human and rat studies, it may be concluded that Inflammoton has a significant effect on humans, and a lesser effect on rats. Seeing as there is little difference in the Inflammotin protein levels between the two dosages in rats, given a high P-value, there is not sufficient evidence that LPS dosages dramatically effect rat protein levels. In addition, given the low P-value, there is sufficient evidence that differing LPS dosages causes a differing amount of Inflammotin protein level growth in humans.